Pharsight

Truvada is owned by Gilead.

Truvada contains Emtricitabine; Tenofovir Disoproxil Fumarate.

Truvada has a total of 4 drug patents out of which 0 drug patents have expired.

Truvada was authorised for market use on 02 August, 2004.

Truvada is available in tablet;oral dosage forms.

Truvada can be used as treatment of hiv; method of treatment of adults infected with hiv-1; treatment of hiv-1 infection in pediatric patients 12 years of age and older, treatment of hiv infection.

The generics of Truvada are possible to be released after 13 January, 2024.

Application	Filing Date	Opposition Party	Legal Status
EP04701819A	2009-03-18	Generics [UK] Limited	Revoked
EP04701819A	2009-03-13	Teva Pharmaceutical Industries LTD.	Revoked

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8592397	GILEAD	Compositions and methods for combination antiviral therapy	Jan, 2024 (7 months from now)
US9457036	GILEAD	Compositions and methods for combination antiviral therapy	Jan, 2024 (7 months from now)
US9744181	GILEAD	Compositions and methods for combination antiviral therapy	Jan, 2024 (7 months from now)
US8716264	GILEAD	Compositions and methods for combination antiviral therapy	Jan, 2024 (7 months from now)

Do you want to check out TRUVADA patents from before 2022?

Drugs and Companies using EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE ingredient

Market Authorisation Date: 02 August, 2004

Treatment: Treatment of hiv; Method of treatment of adults infected with hiv-1; Treatment of hiv-1 infection in pediatric patients 12 years of age and older; Treatment of hiv infection

Dosage: TABLET;ORAL